BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Form 8-K — Nov 16, 2026
BrainStorm Cell Therapeutics (BCLI) reported Q3 2026 results with a net loss of approximately $1.7 million ($0.14 per share), improved from a $2.1 million loss ($0.19 per share) in Q3 2025, as R&D spending fell to $0.5 million from $0.9 million. The company holds only about $0.35 million in cash and restricted cash against $13.2 million in current liabilities, and its forward-looking statements explicitly cite risks around the ability to raise additional capital and continue as a going concern.
Key figures
- Eps
- -$0.14 (Q3 2026 net loss per share)
- Net Income
- -$1.7 million (Q3 2026 net loss)
- Cash Position
- $0.35 million (cash, cash equivalents, and restricted cash as of September 30, 2026)
- Q3 2025 eps
- -$0.19
- Total assets
- $0.84 million
- Accounts payable
- $7.47 million
- Q3 2025 net loss
- -$2.1 million
- Short term loans
- $1.875 million
- Total liabilities
- $13.17 million
- Q3 2025 ga expense
- $1.15 million
- Q3 2025 rd expense
- $0.9 million
- Q3 2026 ga expense
- $1.09 million
- Q3 2026 rd expense
- $0.5 million
- Shares outstanding
- 14,259,377
- Stockholders deficit
- -$12.3 million
- Nine month 2026 net loss
- -$7.7 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.